drugset / Trial / NCT02106923
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly
Timeline
- Start
- 2014-04
- Primary completion
- 2014-06
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 5 mg | — |
| Subject | Empagliflozin | Small molecule | 10 mg | — |
| Subject | Metformin | Small molecule | 750 mg | — |
| Subject | Metformin | Small molecule | 1000 mg | — |
Indications
No indication recorded.